Increasing data entry compliance in PMCF studies

Dr Paul Hercock
Increasing data entry compliance in PMCF studies

Post-Market Clinical Follow-up (PMCF) is a vital component of any successful MDR compliance strategy. MDR Annex XIV Part B describes PMCF as:

…a continuous process that proactively and continuously collects and evaluates clinical data on the use of a CE-marked medical device.

Furthermore, the MDR states that PMCF should relate to the intended purpose of the device and have the aims of:

  • confirming safety and performance throughout the expected lifetime of the device
  • ensuring the continued acceptability of identified risks
  • detecting evidence of any emerging risks that were previously unknown

In order to meet this diverse range of objectives, PMCF studies need to have a solid implementation strategy alongside a robust design. A key part of any PMCF implementation strategy must be a focus on ensuring high levels of data collection compliance and minimising gaps in datasets which could otherwise be held to be potential sources of bias.

5 methods every medical device manufacturer should know to improve their Post-Market Clinical Follow-up studies

Promoting high levels of data entry compliance is a challenge in conducting any clinical investigation. Given that PMCF is intended to run throughout a device’s entire lifetime, devising ways of increasing and maintaining investigator engagement is central to long-term success.

Here are five methods for keeping investigators locked in:

1. Simplicity

Keep it simple. Clinical investigations that try to collect too much data are cumbersome to work with. Investigators often have very limited time and are accommodating data entry around their other commitments, meaning that cumbersome studies cannot be consistently integrated into their working day. Keep it lean and focus only on the essentials.

2. A smooth user experience

Related to simplicity, choose your data entry system carefully. While most studies will now use an eCRF for data entry, not all interfaces are equally easy to work with. Ensure you work with a system that prioritises a smooth user experience and minimises the opportunity for frustration during data entry. It is also worth remembering that hospital-based IT systems may have limited power and are often part of a shared network, meaning that resource-heavy platforms may function poorly. It is also the case that data connectivity for handheld devices may be limited within certain clinical areas.

3. Effective communication

Don’t leave investigators feeling as though they are operating in a vacuum. Keep in touch with them and ensure that heavy recruiters know that their efforts are appreciated. It’s also a great way to ensure that any “niggling” problems are resolved immediately.

4. Reciprocal benefit

PMCF studies have obvious benefits for manufacturers, helping to maintain regulatory approval of their devices and collecting crucial evidence on device safety and performance. Effectively encouraging investigator compliance calls for a PMCF study that also offers benefits for the healthcare professional. Opportunities for publications, podium presentations, and participation in investigator meetings all help, along with facilitating use of the data for internal clinical audits and performance reviews and a fair remuneration structure. At the outset of study design, consult with prospective clinical investigators and gain a deep understanding of what most benefits them.

5. Review, change and update

Take the time to ensure that the study design is working effectively. Make changes in line with investigator feedback and let them know that their comments and ideas have been implemented. Reacting to investigator feedback not only makes them feel valued; it also helps ensure that the study is best aligned to the needs of those who use your devices in practice.

Post-Market Clinical Follow-up is most effective when powered by comprehensive and complete datasets. Using the tips in this article will give your PMCF studies the best chance of meeting these objectives.

Related articles

  1. A precariously balanced pile of ping-pong balls and wooden bars.

    The Shift from MDD to MDR: Key Differences in Demonstrating Equivalence

    This transition has demanded that device safety must be demonstrated with more evidence. We offer tips for winning equivalence claims.

    Kamiya Crabtree Kamiya Crabtree Regulatory Medical Writer
  2. A pen and notepad, resting on a laptop.

    Periodic Safety Update Report: Requirements under EU MDR

    Post-Market Surveillance has become more stringent. We help you to understand what manufacturers need to consider.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  3. An EU flag on a pole flies between two US flags against a blue sky.

    Webinar: From USA to Europe - Accelerating Your Path to the Medical Device Market

    We showed you how to quickly transform your U.S. regulatory work into a compliant EU MDR submission.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  4. A poster frame for our Clinical Evaluation video series featuring Paul Hercock.

    Guide to Clinical Evaluation: Common Pitfalls & Useful Resources

    Part 5 - In the final video from this series, we explore five major pitfalls that often derail clinical evaluations.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  5. A US-style 'changes ahead' warning road sign.

    Device Modifications: When a Simple Change Becomes a Regulatory Nightmare

    As regulatory consultants we understand how minor modifications to a device can often cause disproportionate disruption.

    Kamiya Crabtree Kamiya Crabtree Regulatory Medical Writer
  6. Webinar announcement poster.

    Webinar: Regulatory & Cybersecurity Essentials for medical device software and AI-enabled devices

    Our webinar with Cyber Alchemy addressed bringing AI-enabled medical devices to market with both the right regulatory and cybersecurity foundations.

    Shen May Khoo Shen May Khoo Regulatory Project Lead
  7. A simple jigsaw with iconography representing growth printed on it.

    Leveraging Post-Market Surveillance Data for Continuous Improvement

    PMS isn’t just about compliance, it’s an opportunity for improvement, enhance patient safety & innovate.

    Shen May Khoo Shen May Khoo Regulatory Project Lead
  8. A poster frame for our Clinical Evaluation video series featuring Dr. W. Brambley.

    Guide to Clinical Evaluation: CEP Strategy & CER Structure

    Part 4 - We explore how these guide reviewers through the evidence that supports safey, performance, and conformity.

    Dr Will Brambley Dr Will Brambley Lead Medical Writer
  9. A checklist being ticket-off in pen.

    The Critical Role of Pre-Submission Reviews in EU MDR Clinical Evaluations

    Ensuring your CER is robust and aligned with current standards is critical. How much Clinical Evidence is enough?

    Sandra Gopinath Sandra Gopinath Chief Regulatory Officer

More articles

Need help producing compliant CEPs & CERs? We are offering FREE CEPs to 5 qualifying applicants per week

Get your free CEP